GUTS GUTS
Company Profile ↓Company Overview
GUTS (GUTS) is a publicly traded company listed on with a market capitalization of $104.29M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | -63.17% |
| 6 Months: | +53.24% |
| 3 Months: | -1.30% |
| 1 Month: | -13.94% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.06 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 71.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.00K | 72.00K | 36.00K | 33.00K | 43.00K | 14.00K | - | - | - | - |
| Gross Profit | 2.00K | 25.00K | 11.00K | 14.00K | 19.00K | 7.00K | - | - | - | - |
| Operating Income | -12.11M | -11.88M | -13.87M | -21.54M | -22.98M | -23.79M | -24.76M | -26.08M | -22.69M | -20.82M |
| Net Income | -11.93M | -30.23M | -15.75M | -3.32M | -17.23M | -23.17M | -23.73M | -27.89M | -45.60M | 9.22M |
| Diluted EPS | -7.87 | -16.62 | -9.61 | -0.17 | -0.36 | -0.48 | -0.49 | -0.57 | -0.71 | 0.06 |
| R&D Expense | 9.35M | 9.14M | 9.38M | 14.42M | 16.76M | 19.00M | 19.43M | 21.15M | 17.46M | 15.60M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 120.00K | 93.00K | 0 |
| Gross Profit | 43.00K | 43.00K | - |
| Operating Income | -50.84M | -93.53M | -96.82M |
| Net Income | -77.09M | -68.69M | -140.95M |
| Diluted EPS | -45.29 | -1.62 | -1.86 |
| R&D Expense | 38.04M | 70.47M | 74.54M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 60.96M | 76.21M | 108.08M | 121.40M |
| Current Assets | - | 51.63M | 35.65M | 71.76M | 87.58M |
| Cash & Equivalents | - | 49.27M | 33.21M | 67.46M | 81.54M |
| Inventory | - | 0 | 73.00K | 73.00K | 0 |
| Receivables | - | 0 | 22.00K | 0 | - |
| Total Liabilities | - | 313.27M | 401.27M | 79.65M | 111.94M |
| Current Liabilities | - | 7.31M | 11.19M | 19.77M | 18.33M |
| Long Term Debt | - | 17.76M | 55.15M | 30.16M | 30.59M |
| Total Debt | - | 19.48M | 86.39M | 62.50M | 61.65M |
| Total Equity | - | -252.32M | -325.06M | 28.42M | 9.46M |
| Shares Outstanding | - | 47.55M | 47.90M | 48.76M | 153.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -42.82M | -65.52M | -90.33M |
| Investing Cash Flow | -359.00K | -1.76M | -557.00K |
| Financing Cash Flow | 27.44M | 101.23M | 104.96M |
| Capital Expenditure | -359.00K | -1.76M | -557.00K |
| Free Cash Flow | -43.18M | -67.29M | -90.89M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 35.8% | 46.2% | - |
| Operating Margin % | -42,363.3% | -100,571.0% | - |
| Net Margin % | -64,242.5% | -73,864.5% | - |
| ROE % | 23.7% | -241.7% | -1,490.3% |
| ROCE % | -78.2% | -105.9% | -93.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GUTS
Fractyl Health to Share Q2 Results Aug. 10 at 4:30 p.m. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPRGxGWUw3XzVuSHB5RF9TWVYwWlZzX2pSNHN2eVFiSjFsM1VkUjNWQUZMa2JOSl9Za0MwLTJjOG9TOWdna01KTGtRMWRyd29mX1d3bDRkMGxpUlNlamNuVVl2ZXNHUFdEM1M5ZW1GenRudGxFU2lyNG5hZ1pQbGNXeFFTRE0zZWNrdllZTk…
Fractyl Health, Inc. Revenue Breakdown – NASDAQ:GUTS - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5RcWJJTnJiOGwxX1R3cWdYTXV1dmZmcUNMSG1tUW5ZTXQ2dE5VQTV5WGRKSXVnZlJfalowZ2NYRjQtTUJ2SDVwcHFia3NCcmdfUUVaQjE0T3JWVS05OE9GWFFwckRpbmFjb3gxM3ZoRDJxZ0RZb2M0?oc=5" target="_blank">Fractyl…
Fractyl Health (GUTS) Stock Sees Fair Value Cut As Analysts Weigh Revita Opportunity - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQQmxRb2p6TTdEXzJWVmxkczFyYllZNnNUbWhtR0RqMG9nUnAyLXBJVG1wTEhraHVUTjFCQ09PdXllemRNZk5KUVE4UV8xZlVVcWdZNUtrc21IT1dZU0EyZG5PcWI3TElZUjdCdHBYaUxGTEd4eXN0cWl1VDJoU050Qjg1QXZSRk84TmFtbG…
GUTS|Fractyl Health Inc|Price:0.691|Chg%:+0.006 - TradingKey
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE9VTUJWaE5qTWNZb3lSRXlCTVQwRzNfNklQaUlTcWxDUEw2bkprWHc1eWtxZUs4MEtETmpFTWpJaDI3TGdTU3ZWdjk2N2JCS1pFZUY1ZGxHN19iUQ?oc=5" target="_blank">GUTS|Fractyl Health Inc|Price:0.691|Chg%:+0.0…
Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars - Benzinga
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPdHBuMjF1TkU1M1FRZUdtbFFQOHl0MU5KeVhNTUFSZngzb2RZdGI5UnBlcDkzS0NVWW0zVEQyWTNqN3Vva0xPUUExLThRZ3FiaFVQU2hydDdTd1pTU1k0XzVFaTduN1JuZE1reV9kcGdxMzhCR05HT3ZjSlBBcWEtNUVlUzhIbm96TmJ0ZH…
FRACTYL HEALTH ($GUTS) Releases Q1 2026 Earnings, Stock Rises | GUTS Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQVkZIWnpaTUpGNGRDTDJLUmNsY0NZU2Q4TDRPTWs0MDVTTzk1emwzTmNyb2E0ZEItNXBHYk45R3hEZndCNVpMalBZMHF3UXBmblJ4Xy1RY3duaElnUE9RV0hNZGFsVG1aV09udzR6TXdnamZVUExWb2o5dGpWaW8yRm9pTWZybThFMXZLNl…
GUTS — Frequently Asked Questions
What is the current share price of GUTS?
As of 2026-08-05 17:25 PDT, GUTS trades at $0.68 on NASDAQ/NYSE. Its 52-week range is $0.39 to $2.37.
What is the market capitalisation of GUTS?
GUTS has a market capitalisation of $104.29M on NASDAQ/NYSE.
What is the P/E ratio of GUTS?
GUTS trades at a trailing price-to-earnings (P/E) ratio of -0.37. Its price-to-book (P/B) ratio is 11.02.
Is GUTS a good stock to buy?
This page provides a data-driven analysis of GUTS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.